Search

Displaying results 6231 - 6240 of 9714 in total
  1. Drug

    Santonin

    go.drugbank.com/drugs/DB19377
    ApprovedWithdrawn

    Santonin is a anthelmintic drug that was previously approved in the US to treat certain parasitic infections.

  2. Drug

    Firazorexton

    go.drugbank.com/drugs/DB19440
    Investigational

    Firazorexton is under investigation in clinical trial NCT04096560 (A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy).

  3. Drug

    Raludotatug deruxtecan

    go.drugbank.com/drugs/DB19447
    Investigational

    Raludotatug deruxtecan is under investigation in clinical trial NCT06660654 (A Study of Raludotatug Deruxtecan in Participants With Advanced/metastatic Solid Tumors (Rejoice-pantumor01)).

    Synonyms: immunoglobulin G1-kappa, anti-[Homo sapiens CDH6(cadherin 6, K-cadherin (foetal kidney), cadherin 6 type 2)], humanized monoclonal antibody conjugated to deruxtecan, comprising a linker and a camptothecin
  4. Drug

    Dorocubicel

    go.drugbank.com/drugs/DB19448
    Approved

    following myeloablative conditioning in adult patients for whom a suitable donor is not available. … Dorocubicel is a preparation of cryopreserved allogeneic umbilical cord-derived hematopoietic stem cells and blood progenitors expanded _ex vivo_ using [UM-171].

  5. Drug

    TDI-01

    go.drugbank.com/drugs/DB19450
    Investigational

    TDI-01 is a small molecule is being developed by Beijing Tide Pharmaceutical.

  6. Drug

    Pegunigalsidase alfa

    go.drugbank.com/drugs/DB14992
    ApprovedInvestigational

    Pegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare genetic disorder characterized … to a different glycosylation pattern.

  7. Drug

    Sutimlimab

    go.drugbank.com/drugs/DB14996
    ApprovedInvestigational

    [A245144] Hemolysis in patients with CAD is driven by complement activation, which initiates a cascade that ultimately leads to both intra- and extravascular hemolysis. … Sutimlimab is a first-in-class humanized monoclonal antibody targeted at complement subunit C1s, which is responsible for activating the classic complement pathway.

  8. Drug

    Pateclizumab

    go.drugbank.com/drugs/DB14997
    Investigational

    Pateclizumab is under investigation in clinical trial NCT01225393 (A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared … With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis).

  9. Drug

    Human interferon beta

    go.drugbank.com/drugs/DB14999
    ApprovedInvestigational

    It is therefore a potential drug candidate for SARS-CoV-2 based on viral genetic similarity.[A191733,L12012] … [L12081] Multiple Sclerosis is a devastating neurodegenerative disease that is usually progressive and significantly debilitating with a profound impact on the quality of life.

  10. Drug

    Eflapegrastim

    go.drugbank.com/drugs/DB15001
    ApprovedInvestigational

    [L43135] Eflapegrastim is a form of recombinant human G-CSF comprising a human G-CSF analog coupled to the Fc fragment of human IgG4 via a polyethylene glycol linker. … in which the patient develops an infection during a period of significant neutropenia.